KR EN
Daewoong
Global Healthcare Group
The Best Partner for You

Corporate Governance

Governance of Daewoong Pharmaceutical

Stockholder's meeting

Major Agendas and Resolutions of the General Meeting of Stockholders

22nd Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 28 (Thu), 2024, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 22nd financial statement and consolidated financial statement
Report on internal accounting management system operations status
B. Motioned Bills
Agenda 1: Designation of director (two inside directors / one outside director)
Agenda 2: Designation of auditor
Agenda 3: Approval of director compensation limit
Agenda 4: Approval of auditor compensation limit
Daewoong Pharmaceutical Regular Meeting of Stockholders
No. of stocks issued No. of stocks with voting rights No. of stocks attending No. of stocks attending(majority shareholder and affiliates) No. of stocks attending, excluding majority shareholder and affiliates Voting rights, excluding majority shareholder and affiliates(%)
11,586,575 11,506,270 8,664,874 7,058,478 1,606,396 18.54%
Stockholder's meeting, 22nd
General Stockholder's meeting, 22nd 2024.3.28
Stockholder's meeting, 21st
Agenda Type of Resolution (Ordinary/Special) Motioned Bills Remarks No. of stocks with voting rights(①) No. of stocks attending(A) stocks, For(B)
(Ratio, %)
No. of stocks, Against · Abstain(C)
(Ratio, %)
Agenda 1-1 Ordinary Designation of director (nominee Chang-jae Lee) Approved 11,506,270 8,664,874 7,820,149
(90.25%)
844,725
(9.75%)
Agenda 1-2 Ordinary Designation of director (nominee Eunkyeong Park) Approved 11,506,270 8,664,874 8,632,443
(99.63%)
32,431
(0.37%)
Agenda 1-3 Ordinary Designation of director (nominee Youngmin Cho) Approved 11,506,270 8,664,874 8,638,855
(99.70%)
26,019
(0.30%)
Agenda 2 Ordinary Designation of auditor (nominee Geon Haeng Lee) Approved 11,506,270 8,664,874 1,440,057
(97.22%)
41,126
(2.78%)
Agenda 3 Ordinary Approval of director compensation limit (3 Bil. Won) Approved 11,069,208 8,664,874 8,623,882
(99.53%)
40,992
(0.47%)
Agenda 4 Ordinary Approval of auditor compensation limit (200 Mil. Won) Approved 11,069,208 8,664,874 8,624,900
(99.54%)
39,974
(0.46%)
21st Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 29 (Tue), 2023, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 21st financial statement and consolidated financial statement
Report on internal accounting management system operations status
B. Motioned Bills
Agenda 1: Designation of director (one inside director / one outside director)
Agenda 2: Approval of director compensation limit
Agenda 3: Approval of auditor compensation limit
Daewoong Pharmaceutical Regular Meeting of Stockholders
No. of stocks issued No. of stocks with voting rights No. of stocks attending No. of stocks attending(majority shareholder and affiliates) No. of stocks attending, excluding majority shareholder and affiliates Voting rights, excluding majority shareholder and affiliates(%)
11,586,575 11,069,208 8,666,832 6,528,338 2,138,494 24.67%
Stockholder's meeting, 21st
General Stockholder's meeting, 21st 2023.3.29
Stockholder's meeting, 21st
Agenda Type of Resolution (Ordinary/Special) Motioned Bills Remarks No. of stocks with voting rights(①) No. of stocks attending(A) stocks, For(B)
(Ratio, %)
No. of stocks, Against · Abstain(C)
(Ratio, %)
Agenda 1-1 Ordinary Designation of director (nominee Seongsoo Park) Approved 11,069,208 8,666,832 8,615,979
(99.41%)
50,853
(0.59%)
Agenda 1-2 Ordinary Designation of director (nominee Yong-Jin Kim) Approved 11,069,208 8,666,832 8,631,400
(99.59%)
35,432
(0.41%)
Agenda 2 Ordinary Approval of director compensation limit (3 Bil. Won) Approved 11,069,208 8,666,832 8,631,364
(99.59%)
35,468
(0.41%)
Agenda 3 Ordinary Approval of auditor compensation limit (200 Mil. Won) Approved 11,069,208 8,666,832 8,631,554
(99.59%)
35,278
(0.41%)
20th Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 29 (Tue), 2022, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 20th financial statement and consolidated financial statement
Report on internal accounting management system operations status
Report on outside auditor designation
B. Motioned Bills
Agenda 1: Change of articles of association
Agenda 2: Designation of director (one outside director)
Agenda 3: Approval of director compensation limit
Agenda 4: Approval of auditor compensation limit
Agenda 5: Approval of granting stock options
Daewoong Pharmaceutical Regular Meeting of Stockholders
No. of stocks issued No. of stocks with voting rights No. of stocks attending No. of stocks attending(majority shareholder and affiliates) No. of stocks attending, excluding majority shareholder and affiliates Voting rights, excluding majority shareholder and affiliates(%)
11,586,575 11,069,208 8,274,125 6,658,336 1,615,789 19.53%
Stockholder's meeting, 20th
General Stockholder's meeting, 20th 2022.3.29
Stockholder's meeting, 20th
Agenda Type of Resolution (Ordinary/Special) Motioned Bills Remarks No. of stocks with voting rights(①) No. of stocks attending(A) stocks, For(B)
(Ratio, %)
No. of stocks, Against · Abstain(C)
(Ratio, %)
Agenda 1 Special Change of articles of association Approved 11,069,208 8,274,125 8,091,942
(97.80%)
182,183
(2.20%)
Agenda 2 Ordinary Designation of director(nominee Dae-duk Kim) Approved 11,069,208 8,274,125 8,200,622
(99.11%)
73,503
(0.89%)
Agenda 3 Ordinary Approval of director compensation limit (3 Bil. Won) Approved 11,069,208 8,274,125 7,341,889
(88.73%)
932,236
(11.27%)
Agenda 4 Ordinary Approval of auditor compensation limit (200 Mil. Won) Approved 11,069,208 8,274,125 8,197,876
(99.08%)
76,249
(0.92%)
Agenda 5 Ordinary Approval of granting stock options Approved 11,069,208 8,274,125 8,196,118
(99.06%)
78,007
(0.94%)
19th Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 26 (Fri), 2021, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 19th financial statement and consolidated financial statement
Report on internal accounting management system operations status
Report on outside auditor designation
B. Motioned Bills
Agenda 1: Change of articles of association
Agenda 2: Designation of directors (three executive directors, two outside directors)
Agenda 3: Designation of auditor (one fulltime auditor)
Agenda 4: Approval of director compensation limit
Agenda 5: Approval of auditor compensation limit
Agenda 6: Approval of granting stock options
18th Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 30 (Fri), 2020, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 18th financial statement and consolidated financial statement
Report on internal accounting management system operations status
B. Motioned Bills
Agenda 2: Change of articles of association
Agenda 3: Case of appointing auditors
Agenda 4: Approval of director compensation limit
Agenda 5: Approval of auditor compensation limit
17th Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 22 (Fri), 2019, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 17th financial statement and consolidated financial statement
Report on internal accounting management system operations status
B. Motioned Bills
Agenda 1: Change of articles of association
Agenda 2: Approval of director compensation limit
Agenda 3: Approval of auditor compensation limit
Agenda 4: Approval of granting stock options
16th Daewoong Pharmaceutical Regular Meeting of Stockholdersview
1. Time
March 23 (Fri), 2018, 09:00
2. Location
Daewoong Pharmaceutical HQ Bear Hall
3. Meeting Objectives
A. Report Items
Audit report and sales report
Report on the 16th financial statement and consolidated financial statement
B. Motioned Bills
Agenda 1: Case of appointing directors (2 in-company directors, 1 outside director)
Agenda 2: Approval of director compensation limit
Agenda 3: Approval of auditor compensation limit
Agenda 4: Change of articles of association